Latest study: Biosimilar drugs are expected to benefit patients with ankylosing spondylitis

The first issue of The Lancet Rheumatology was released on August 28, 2019, London time. In this issue, a study by the team of Professor Xu Huji from the Tsinghua University School of Medicine for the treatment of ankylosing spondylitis was published...

"The Power of Science" Zhiben Era

The first issue of The Lancet Rheumatology was released on August 28, 2019, London time. In this issue, a study by the team of Professor Xu Huji from the Tsinghua University School of Medicine for the treatment of ankylosing spondylitis was published...

Domestic biosimilar drugs "answer" rheumatology problems

The first issue of The Lancet Rheumatology was released on August 28, 2019, London time. In this issue, a study by the team of Professor Xu Huji from the Tsinghua University School of Medicine for the treatment of ankylosing spondylitis was published...

Innovative domestic anti-tumor drugs help the fight against health and poverty alleviation

The first issue of The Lancet Rheumatology was released on August 28, 2019, London time. In this issue, a study by the team of Professor Xu Huji from the Tsinghua University School of Medicine for the treatment of ankylosing spondylitis was published...

Good news for cancer patients! New domestic anti-cancer drug approved for marketing, remission rate reached 80.4%

The first issue of The Lancet Rheumatology was released on August 28, 2019, London time. In this issue, a study by the team of Professor Xu Huji from the Tsinghua University School of Medicine for the treatment of ankylosing spondylitis was published...